[Clinical experience with thymostimulin (TP-1) therapy. Preliminary findings]

Area of Science:

• Immunology
• Pharmacology
• Clinical Medicine

Background:

• Thymus humoral factors are crucial for immune system development and function.
• Immunodeficiency disorders, both primary and acquired, present significant health challenges.
• Bovine thymic extract (TP 1-Thymostimulin) is investigated for its potential immunostimulant properties.

Purpose of the Study:

• To evaluate the immunostimulant effects of a bovine thymic extract (TP 1-Thymostimulin).
• To assess the clinical and immunological impact of TP 1-Thymostimulin in patients with various immunodeficiency conditions and other diseases.

Main Methods:

• A cohort of patients with primary immunodeficiency, acquired immunodeficiency (due to aging, lung neoplasm, or recurrent herpes simplex labialis), chronic active hepatitis HBsAg+, and Behçet's syndrome were administered TP 1-Thymostimulin.
• Immunological parameters and clinical status were monitored over a six-month period.

Main Results:

• Patients with primary and acquired immunodeficiencies exhibited normalized immunological parameters and clinical improvement.
• A clinical improvement was noted in patients with lung neoplasms.
• No significant clinical or immunological improvement was observed in patients with chronic active hepatitis HBsAg+.
• The patient with Behçet's syndrome experienced a reduction in recurrent uveitis.

Conclusions:

• TP 1-Thymostimulin demonstrates efficacy as an immunostimulant in primary and acquired immunodeficiencies, leading to both immunological and clinical benefits.
• The extract shows potential therapeutic value in specific conditions like lung neoplasm and Behçet's syndrome (uveitis).
• TP 1-Thymostimulin was not effective in improving outcomes for patients with chronic active hepatitis HBsAg+.